Skip to main content

Table 3 Total adverse effects in SCLC patients

From: The benefits and risks of pembrolizumab in combination with chemotherapy as first-line therapy in small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized control trials

Adverse events

Studies involved

Event/total

%

Hematological system AEs

 Neutropenia

2

229/254

90.16

 Anemia

4

174/327

53.21

 Platelet count decrease

2

91/261

34.87

 WBC count decrease

4

91/346

26.30

 Febrile neutropenia

2

7/66

10.61

Digestive system AEs

 Dysphagia

2

30/73

41.96

 Esophagitis

2

25/73

32.89

 Nausea

5

118/363

32.51

 Constipation

4

83/332

25.00

 Decreased appetite

1

67/228

29.39

 Diarrhea

5

76/363

20.94

 Vomiting

2

40/254

15.75

 Increased aspartate transaminase level

1

6/45

13.33

 Norexia

3

13/99

13.13

 Abdominal pain

1

5/45

11.11

 Stomatitis

1

1/26

3.85

 Duodenitis

1

1/40

2.50

 Pancreatitis

1

1/40

2.50

Respiratory system AEs

 Dyspnea

4

76/346

21.97

 Pneumonia

3

53/294

18.03

 Lung infection

1

5/40

12.50

 Respiratory failure

1

1/40

2.50

Skin AEs

 Rash

6

51/396

12.88

 Pruritus

5

46/372

12.37

 Dry skin

1

2/24

8.33

 Excessive tearing

1

2/24

8.33

 Radiation dermatitis

2

6/73

8.22

Circulative system AEs

 Peripheral edema

2

22/268

8.21

 Pericarditis

1

1/40

2.50

 Sinus tachycardia

1

1/40

2.50

 Flushing

1

1/40

2.50

Nervous system AEs

 Peripheral sensory neuropathy

2

17/66

25.76

 Peripheral motor neuropathy

1

3/26

11.54

 Neuropathy

1

5/45

11.11

Motor system AEs

 Myalgia

2

12/50

24.00

 Arthralgia

2

10/64

15.63

 Back pain

2

33/273

12.09

 Arthritis

1

2/40

5.00

 Muscle weakness

1

1/33

3.03

 Chest wall pain

1

1/40

2.50

Electrolyte disturbance AEs

 Hyponatremia

3

32/294

10.88

 Hypokalemia

1

3/40

7.50

Urological system AEs

 Creatinine increased

1

9/40

22.50

 Chronic kidney disease

1

2/40

5.00

Endocrine system AEs

 Type I diabetes mellitus

1

3/26

11.54

 Hypothyroidism

2

24/254

9.49

Systemic AEs

 Fatigue

5

121/370

32.70

 Asthenia

3

58/278

20.86

 Pyrexia

1

35/228

15.35

 Generalized weakness

1

5/45

11.11

Others AEs

 Alopecia

1

75/228

32.89

 Cough

4

71/346

20.52

 Dizziness

3

48/229

16.05

 Noncardiac chest pain

1

6/45

13.33

 Headache

4

39/332

11.75

 Insomnia

2

27/252

10.71

 Pain

1

3/33

9.09

 Confusion

1

1/40

2.50

  1. Abbreviations: AEs adverse effects, SCLC small-cell lung cancer